EDV technology – Talk Bio

Actionable Insights Powered by AI

Jennifer Doudna’s Azalea Therapeutics Launches with $82M to Advance In Vivo CAR-T Using Novel CRISPR Delivery Technology

17 hours ago talkbio0Tagged Autoimmune Diseases, Azalea Therapeutics, B-cell malignancies, Cancer Therapeutic Procedure, CAR-T, Clustered Regularly Interspaced Short Palindromic Repeats, EDV technology, Funding, Gene Modification, in vivo, Jennifer Doudna, Series A

Jennifer Doudna; Azalea Therapeutics; CRISPR; in vivo CAR-T; gene editing; EDV technology; cancer therapy; autoimmune disease; Series A funding; B-cell malignancies